MEN2A is characterized by bilateral, multicentric MTC in more than 90% of index patients (carrying germline RET mutations in codon 634; i.e. those presenting with MTC at diagnosis in the absence of screening), pheochromocytomas in 50% and primary hyperparathyroidism in 10 to 20%. The gene discussed is RET; the disease is primary hyperparathyroidism.